AZN Share PerformanceMore
|52 week high||5,520 22/06/17|
|52 week low||3,996 06/12/16|
|52 week change||219 (4.43%)|
|4 week volume||42,364,590 21/09/17|
Latest News« previous» nextMore
17/10/2017 - 08:28 StockMarketWire
AstraZeneca and MedImmune, its global biologics research and development arm, have announced that the US Food and D...
17/10/2017 - 07:00 RNS
RNS Number: 7316T AstraZeneca PLC 17 October 2017 17 October 2017 07:00 BST US FDA ACCEPTS SUPPLEMENTAL BIOLOGICS LICENSE APPLICATION FOR IMFINZI IN LOCALLY ADVANCED UNRESECTABLE NON-SMALL CELL LUNG CANCER Imfinzi granted Priority Review Acceptance follows FDA's Breakthrough Therapy Designation Astra...
16/10/2017 - 12:50 StockMarketWire
Credit Suisse today upgrades its investment rating on AstraZeneca PLC (LON:AZN) to outperform (from neutral) and rai...
16/10/2017 - 09:30 StockMarketWire
Jefferies International today reaffirms its hold investment rating on AstraZeneca PLC (LON:AZN) and raised its price tar...
11/10/2017 - 11:37 Interactive Investor
If hedge funds smell blood they'll attack vulnerable companies for profit. David Brenchley reveals this fund's short positio...
09/10/2017 - 08:10 StockMarketWire
HSBC today reaffirms its reduce investment rating on AstraZeneca PLC (LON:AZN) and raised its price target to 4150p (f...
09/10/2017 - 07:19 StockMarketWire
AstraZeneca has announced that the US Food and Drug Administration has granted breakthrough therapy designation fo...
09/10/2017 - 07:00 RNS
RNS Number: 0020T AstraZeneca PLC 09 October 2017 9 October 2017 07:00 BST TAGRISSO GRANTED BREAKTHROUGH THERAPY DESIGNATION BY US FDA FOR THE 1ST-LINE TREATMENT OF PATIENTS WITH EGFR MUTATION-POSITIVE NON-SMALL CELL LUNG CANCER Designation based on positive Phase III FLAURA trial results Sixth...
Latest discussion posts More
“The European Medicines Agency accepts for review AstraZeneca's (NYSE:AZN) marketing application seeking approval for Imfinzi (durvalumab) for the treatment of patients with ...”▼
“AstraZeneca has announced that the US Food and Drug Administration has granted breakthrough therapy designation for Tagrisso (osimertinib) for the first-line treatment of ...”▼
“up another 10+%”▼
Codes & Symbols
|Symbols||AZN, LSE:AZN, AZN.L, AZN:LN, LON:AZN, XLON:AZN|